Company profile · free preview

Boston Scientific

BSX · Updated 10/24/2026

Revenue

$20.1B

Fiscal 2025

Net income

—

Fiscal 2025

Free cash flow

$3.7B

Fiscal 2025

Net cash / (debt)

—

Fiscal 2025

Five-year financials

Fiscal year20252024202320222021
Revenue$20.1B$16.7B$14.2B$12.7B$11.9B
Net income—————
Diluted EPS—————
Operating cash flow$4.5B$3.4B$2.5B$1.5B$1.9B
Free cash flow$3.7B$2.6B$1.8B$938.0M$1.3B
Cash$2.0B$414.0M$865.0M$928.0M$1.9B
Total debt—————

Where the cash went

Cumulative, fiscal 2021–2025, straight from the reported cash-flow statements.

Reinvested in capex

25.4%

of operating cash flow

Returned to owners

—

of free cash flow (buybacks + dividends)

Diluted share count

—

change 2021–2025

Capital expenditure $3.5BBar width = share of $13.9B operating cash flow
Operating cash flow$13.9B
Capital expenditure($3.5B)
Free cash flow$10.3B
Share buybacks—
Dividends paid—
Acquisitions (net)—
Net debt issued / (repaid)—
Stock-based compensation (non-cash)—

"—" means a year didn't report that line, so no total is shown rather than an estimate.

SEC filings

  • 10-K · period 2025-12-312026-02-17EDGAR

Ask anything about Boston Scientific's filings

"What changed since last year?" "Where is the cash going?" Get answers drawn straight from the filings.

Start researching free

More companies